Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 20/20 | 0.83 |
| ▸ | FLT4 | P35916 | 20/20 | 0.83 |
| ▸ | KDR | P35968 | 20/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1581237 | 0.91 | FLT1 (1.00) | FLT1FLT4KDR | |
| SCHEMBL5489707 | 0.87 | FLT1 (0.86) | FLT1FLT4KDR | |
| SCHEMBL5958983 | 0.86 | FLT1 (0.84) | FLT1FLT4KDR | |
| SCHEMBL5959047 | 0.86 | FLT1 (0.80) | FLT1FLT4KDR | |
| SCHEMBL31310429 | 0.86 | FLT1 (0.83) | FLT1FLT4KDR | |
| SCHEMBL5958902 | 0.86 | FLT1 (1.00) | FLT1FLT4KDR | |
| SCHEMBL5958926 | 0.86 | FLT1 (1.00) | FLT1FLT4KDR | |
| SCHEMBL31310442 | 0.86 | FLT1 (0.83) | FLT1FLT4KDR | |
| SCHEMBL5959146 | 0.86 | FLT1 (1.00) | FLT1FLT4KDR | |
| SCHEMBL5491628 | 0.85 | FLT1 (1.00) | FLT1FLT4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183320-B2 | Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents | ELI LILLY AND COMPANY (US) | 2007-02-27 | — | — | US | disclosed |
| EP-1401806-B1 | BENZOYLSULFONAMIDES AND SULFONYLBENZAMIDINES FOR USE AS ANTITUMOUR AGENTS | LILLY CO ELI (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20040157741-A1 | Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents | ELI LILLY AND COMPANY | 2004-08-12 | — | — | US | disclosed |
| EP-1401806-A1 | BENZOYLSULFONAMIDES AND SULFONYLBENZAMIDINES FOR USE AS ANTITUMOUR AGENTS | ELI LILLY AND COMPANY (US) | 2004-03-31 | — | — | EP | disclosed |
| WO-2002098848-A1 | BENZOYLSULFONAMIDES AND SULFONYLBENZAMIDINES FOR USE AS ANTITUMOUR AGENTS | ELI LILLY AND COMPANY (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157741-A1 | Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents | GLS2, GLS, MCL1 | FLT1 1396/4885FLT4 1421/4885KDR 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.